Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
Date:1/11/2012

CAMBRIDGE, Mass., Jan. 11, 2012 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 1 clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR).

The Phase 1 study will assess the safety of MM-151 and determine the recommended Phase 2 dose. Four sites are currently expected to participate in this trial.  The first patient was enrolled at the Indiana University Health Arnett and Horizon Oncology clinical site.

About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process.  Merrimack currently has five targeted therapeutic oncology candidates in clinical development.

Contact:  Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com

Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, betsy@raymondstevenson.com


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
2. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
3. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
4. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
5. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
6. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
10. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
11. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... WARSAW, Ind. , April 20, 2017  Zimmer ... leader in musculoskeletal healthcare, today announced that it will ... Health Care Conference at the InterContinental Hotel in ... 2017.  Zimmer Biomet will present at 11:20 a.m. Eastern ... can be accessed via Zimmer Biomet,s Investor Relations website ...
(Date:4/20/2017)... MARLBOROUGH, Mass. , April 20, 2017 /PRNewswire/ ... company developing innovative therapeutics that address significant unmet ... new data from the Company,s consumer product development ... technology, at the Society for Investigative Dermatology (SID) ... is to advance and promote the sciences relevant ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Semrock’s highly popular SearchLight Spectra Viewer Plotting ... for fluorescence microscopists and optical system designers, enabling The Right Solution, Right Now. ... globe, SearchLight has become a tremendously popular tool for the fluorescence imaging community” ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... Economics Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis ... (IRR) field. Offering practical takeaways to apply immediately to IRR programs, the report ...
(Date:4/27/2017)... Minneapolis, Minnesota (PRWEB) , ... April 27, 2017 ... ... Smith and her husband Dan Gasby the 2017 Public Leadership in Neurology Award ... Bob Woodruff, retired professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael ...
(Date:4/27/2017)... ... 27, 2017 , ... Goodcents Deli Fresh Subs announced a franchise expansion agreement ... year. , The first new location will open at the corner of 27th ... and Northern Lights Drive this fall. And the third location is in the process ...
(Date:4/27/2017)... ... April 27, 2017 , ... Plastic Surgery Associates is excited to announce ... present at the upcoming Aesthetic Meeting. Held in San Diego, at the San Diego ... Canales will lend their expertise to the Premier Global Hot Topics session, speaking on ...
Breaking Medicine News(10 mins):